Although public awareness of breast cancer is generally high, this is not the case for metastatic breast cancer, and the Association of Community Cancer Centers (ACCC) is partnering with leading cancer advocacy groups on a new project to change that.
As survivorship rates for cancer have increased, so has the awareness of the emotional toll cancer has on a person rather than just the physical.
The FDA has approved dronabinol oral solution (Syndros) to treat chemotherapy-induced nausea and vomiting (CINV) in patients who have not responded to conventional antiemetic therapies.
More than 1 million people in the United States have been diagnosed with a melanoma and are at risk for developing a second primary melanoma.
National guidelines recommend that women with a personal history of ovarian cancer be tested for the BRCA mutation. Approximately 1.3% of women will develop ovarian cancer, according to the National Cancer Institute, but that risk increases to an estimated 39% in women with the BRCA1 mutation and 11% to 17% in women who inherit the BRCA2 mutation.
Caring for loved ones in the midst of major health issues is taxing for anyone, but a new report reveals that caregivers of patients with cancer experience even more stress and responsibilities than caregivers of patients with other diseases.
Results of a small study exploring the use of frozen gloves and socks in women receiving paclitaxel chemotherapy for their breast cancer suggest the approach may hold promise for the relief of chemotherapy-induced peripheral neuropathy (CIPN).
Cancer survivors often experience physical and psychosocial long-term and late effects after treatment ends.
With a shortage of oncologists in the United States, nurse practitioners are ready to take over some of the responsibilities previously carried out by physicians in survivorship care.
Researchers from the University of Arizona in Tucson and the American Cancer Society conducted a systematic literature review to examine associations between adherence to established cancer prevention guidelines and overall cancer incidence and mortality.
Duration of aromatase inhibitor (AI) therapy for postmenopausal women with early stage breast cancer has been debated for some time.
A cancer diagnosis comes with an array of emotions. On top of what is happening internally to an individual’s body, patients first see what is happening externally—most noticeably their looks.
Survivors of childhood leukemia who received chemotherapy involving high concentrations of methotrexate were found to be more likely to struggle with brain functionality in the long term.
Oncology nurses receive a steady stream of information on the benefits of exercise for health and wellness—not just a way to help prevent cancer and lower risk for the general population, but to improve quality of life and reduce the risk of recurrence for patients and survivors.
For uninsured patients who are at a high risk for colorectal cancer (CRC), performing free screening colonoscopies can identify cancer at an earlier stage and appears to be cost neutral from a hospital system perspective.
Young black women with breast cancer are much less likely to have BRCA testing or, if they carry a BRCA mutation, to undergo risk-reducing prophylactic mastectomy or salpingo-oophorectomy.
In a small pilot study, presented at the recent 2016 ASCO Annual Meeting, researchers are evaluating whether wearable activity monitors can help clinicians to better assess patient well-being between office visits.
An analysis of over 28,000 patients younger than 65 with incurable cancers found that approximately three-fourths of them received aggressive care within the last 30 days of life and one-third died in the hospital.
On June 6, 2016, during the annual meeting of the American Society of Clinical Oncology (ASCO), Vice President Joe Biden unveiled the Genomic Data Commons (GDC) project.
Researchers in France have found that patients with lung cancer who used a web-based app to report and track their symptoms achieved impressive gains in survival compared with individuals who were followed using standard protocols.
Women who extended their adjuvant therapy with an aromatase inhibitor (AI) to 10 years after treatment for their early-stage HR-positive breast cancer reduced their risk of recurrence by more than a third and experienced no new toxicities or worsening of quality of life.
Researchers are hoping that a new nationwide effort aimed at helping patients to share their tumor samples and clinical information will lead to new discoveries and better treatments for metastatic breast cancer.
Women with a history of infertility, and have undergone hormonal fertility treatment have denser breast tissue, which may increase their risk of developing breast cancer, according to a study published in the journal Breast Cancer Research.
